|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: STX3 |
Gene summary for STX3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | STX3 | Gene ID | 6809 |
| Gene name | syntaxin 3 | |
| Gene Alias | DIAR12 | |
| Cytomap | 11q12.1 | |
| Gene Type | protein-coding | GO ID | GO:0001505 | UniProtAcc | Q13277 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6809 | STX3 | HTA11_3410_2000001011 | Human | Colorectum | AD | 7.44e-09 | 4.41e-01 | 0.0155 |
| 6809 | STX3 | HTA11_2487_2000001011 | Human | Colorectum | SER | 4.16e-08 | 6.40e-01 | -0.1808 |
| 6809 | STX3 | HTA11_1938_2000001011 | Human | Colorectum | AD | 4.00e-13 | 8.11e-01 | -0.0811 |
| 6809 | STX3 | HTA11_78_2000001011 | Human | Colorectum | AD | 6.61e-08 | 5.87e-01 | -0.1088 |
| 6809 | STX3 | HTA11_347_2000001011 | Human | Colorectum | AD | 3.60e-21 | 8.10e-01 | -0.1954 |
| 6809 | STX3 | HTA11_411_2000001011 | Human | Colorectum | SER | 3.30e-05 | 1.01e+00 | -0.2602 |
| 6809 | STX3 | HTA11_2112_2000001011 | Human | Colorectum | SER | 5.51e-05 | 8.92e-01 | -0.2196 |
| 6809 | STX3 | HTA11_83_2000001011 | Human | Colorectum | SER | 2.45e-08 | 6.73e-01 | -0.1526 |
| 6809 | STX3 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.58e-07 | 5.01e-01 | -0.1464 |
| 6809 | STX3 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.53e-16 | 9.19e-01 | -0.059 |
| 6809 | STX3 | HTA11_2992_2000001011 | Human | Colorectum | SER | 6.96e-08 | 9.60e-01 | -0.1706 |
| 6809 | STX3 | HTA11_5212_2000001011 | Human | Colorectum | AD | 5.26e-03 | 6.97e-01 | -0.2061 |
| 6809 | STX3 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.78e-04 | 4.76e-01 | 0.096 |
| 6809 | STX3 | HTA11_7663_2000001011 | Human | Colorectum | SER | 1.41e-03 | 6.49e-01 | 0.0131 |
| 6809 | STX3 | HTA11_6801_2000001011 | Human | Colorectum | SER | 1.75e-07 | 9.81e-01 | 0.0171 |
| 6809 | STX3 | HTA11_10711_2000001011 | Human | Colorectum | AD | 2.70e-06 | 5.72e-01 | 0.0338 |
| 6809 | STX3 | HTA11_7696_3000711011 | Human | Colorectum | AD | 9.19e-17 | 6.95e-01 | 0.0674 |
| 6809 | STX3 | HTA11_6818_2000001021 | Human | Colorectum | AD | 8.50e-10 | 7.24e-01 | 0.0588 |
| 6809 | STX3 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 4.47e-24 | 8.65e-01 | 0.294 |
| 6809 | STX3 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 7.21e-13 | 7.29e-01 | 0.281 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0099003 | Colorectum | AD | vesicle-mediated transport in synapse | 57/3918 | 200/18723 | 6.53e-03 | 4.06e-02 | 57 |
| GO:0048284 | Colorectum | AD | organelle fusion | 42/3918 | 141/18723 | 8.04e-03 | 4.73e-02 | 42 |
| GO:00726591 | Colorectum | SER | protein localization to plasma membrane | 92/2897 | 284/18723 | 6.36e-13 | 1.86e-10 | 92 |
| GO:19038291 | Colorectum | SER | positive regulation of cellular protein localization | 86/2897 | 276/18723 | 3.61e-11 | 6.11e-09 | 86 |
| GO:19907781 | Colorectum | SER | protein localization to cell periphery | 98/2897 | 333/18723 | 6.09e-11 | 9.57e-09 | 98 |
| GO:19030761 | Colorectum | SER | regulation of protein localization to plasma membrane | 36/2897 | 104/18723 | 1.12e-06 | 5.18e-05 | 36 |
| GO:19054751 | Colorectum | SER | regulation of protein localization to membrane | 52/2897 | 175/18723 | 1.31e-06 | 6.04e-05 | 52 |
| GO:19043751 | Colorectum | SER | regulation of protein localization to cell periphery | 40/2897 | 125/18723 | 2.85e-06 | 1.16e-04 | 40 |
| GO:00901501 | Colorectum | SER | establishment of protein localization to membrane | 68/2897 | 260/18723 | 5.55e-06 | 2.01e-04 | 68 |
| GO:19054771 | Colorectum | SER | positive regulation of protein localization to membrane | 33/2897 | 106/18723 | 3.83e-05 | 9.82e-04 | 33 |
| GO:19030781 | Colorectum | SER | positive regulation of protein localization to plasma membrane | 22/2897 | 62/18723 | 8.58e-05 | 1.88e-03 | 22 |
| GO:19043771 | Colorectum | SER | positive regulation of protein localization to cell periphery | 23/2897 | 69/18723 | 1.78e-04 | 3.30e-03 | 23 |
| GO:00988761 | Colorectum | SER | vesicle-mediated transport to the plasma membrane | 37/2897 | 136/18723 | 3.08e-04 | 5.00e-03 | 37 |
| GO:00160501 | Colorectum | SER | vesicle organization | 69/2897 | 300/18723 | 3.59e-04 | 5.61e-03 | 69 |
| GO:00457851 | Colorectum | SER | positive regulation of cell adhesion | 93/2897 | 437/18723 | 6.78e-04 | 9.04e-03 | 93 |
| GO:00224061 | Colorectum | SER | membrane docking | 25/2897 | 86/18723 | 9.88e-04 | 1.17e-02 | 25 |
| GO:00068871 | Colorectum | SER | exocytosis | 75/2897 | 352/18723 | 2.05e-03 | 2.03e-02 | 75 |
| GO:01400561 | Colorectum | SER | organelle localization by membrane tethering | 22/2897 | 77/18723 | 2.46e-03 | 2.32e-02 | 22 |
| GO:00726592 | Colorectum | MSS | protein localization to plasma membrane | 113/3467 | 284/18723 | 3.23e-17 | 1.55e-14 | 113 |
| GO:19907782 | Colorectum | MSS | protein localization to cell periphery | 120/3467 | 333/18723 | 2.02e-14 | 5.47e-12 | 120 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa041305 | Esophagus | ESCC | SNARE interactions in vesicular transport | 28/4205 | 33/8465 | 2.75e-05 | 1.32e-04 | 6.75e-05 | 28 |
| hsa0413012 | Esophagus | ESCC | SNARE interactions in vesicular transport | 28/4205 | 33/8465 | 2.75e-05 | 1.32e-04 | 6.75e-05 | 28 |
| hsa04130 | Liver | Cirrhotic | SNARE interactions in vesicular transport | 18/2530 | 33/8465 | 2.64e-03 | 1.10e-02 | 6.76e-03 | 18 |
| hsa041301 | Liver | Cirrhotic | SNARE interactions in vesicular transport | 18/2530 | 33/8465 | 2.64e-03 | 1.10e-02 | 6.76e-03 | 18 |
| hsa041302 | Liver | HCC | SNARE interactions in vesicular transport | 25/4020 | 33/8465 | 8.78e-04 | 3.38e-03 | 1.88e-03 | 25 |
| hsa041303 | Liver | HCC | SNARE interactions in vesicular transport | 25/4020 | 33/8465 | 8.78e-04 | 3.38e-03 | 1.88e-03 | 25 |
| hsa041304 | Oral cavity | OSCC | SNARE interactions in vesicular transport | 28/3704 | 33/8465 | 1.31e-06 | 7.18e-06 | 3.66e-06 | 28 |
| hsa0413011 | Oral cavity | OSCC | SNARE interactions in vesicular transport | 28/3704 | 33/8465 | 1.31e-06 | 7.18e-06 | 3.66e-06 | 28 |
| hsa0413021 | Oral cavity | LP | SNARE interactions in vesicular transport | 22/2418 | 33/8465 | 6.00e-06 | 4.76e-05 | 3.07e-05 | 22 |
| hsa0413031 | Oral cavity | LP | SNARE interactions in vesicular transport | 22/2418 | 33/8465 | 6.00e-06 | 4.76e-05 | 3.07e-05 | 22 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| STX3 | SNV | Missense_Mutation | rs201661485 | c.460N>A | p.Glu154Lys | p.E154K | Q13277 | protein_coding | deleterious(0.03) | probably_damaging(0.998) | TCGA-D8-A1JN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozolum | SD |
| STX3 | SNV | Missense_Mutation | novel | c.458T>A | p.Leu153His | p.L153H | Q13277 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-E2-A1LL-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | docetaxel | PD |
| STX3 | SNV | Missense_Mutation | novel | c.179N>G | p.Tyr60Cys | p.Y60C | Q13277 | protein_coding | deleterious(0) | probably_damaging(0.967) | TCGA-E2-A574-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| STX3 | SNV | Missense_Mutation | c.334N>A | p.Asp112Asn | p.D112N | Q13277 | protein_coding | deleterious(0.02) | benign(0.254) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| STX3 | SNV | Missense_Mutation | c.583N>A | p.Glu195Lys | p.E195K | Q13277 | protein_coding | deleterious(0) | probably_damaging(0.948) | TCGA-C5-A7CO-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | SD | |
| STX3 | SNV | Missense_Mutation | c.755N>C | p.Lys252Thr | p.K252T | Q13277 | protein_coding | deleterious(0) | probably_damaging(0.976) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| STX3 | SNV | Missense_Mutation | novel | c.577G>A | p.Glu193Lys | p.E193K | Q13277 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-VS-A8QC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | paclitaxel | PD |
| STX3 | SNV | Missense_Mutation | c.249N>C | p.Glu83Asp | p.E83D | Q13277 | protein_coding | tolerated(1) | benign(0.009) | TCGA-A6-2682-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5 | PD | |
| STX3 | SNV | Missense_Mutation | rs767164155 | c.451N>T | p.Arg151Trp | p.R151W | Q13277 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| STX3 | SNV | Missense_Mutation | c.281N>C | p.Lys94Thr | p.K94T | Q13277 | protein_coding | deleterious(0.02) | probably_damaging(0.926) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |